Shanghai Kehua Bio-Engineering Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

1.22

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

0.03%

Rev. gr., 5y

3.93%

Revenues

2.41b

-65.37%

Net income

-234m

CFO

-475m

Dividend

May 10, 20230.6 CNY/sh

Profile

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.

URL

https://www.skhb.com/

IPO date

Jul 21, 2004

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	2,413,526 -65.37%	6,969,863 43.58%
Cost of revenue	2,092,471	4,544,389
Unusual Expense (Income)
NOPBT	321,056	2,425,474
NOPBT Margin	13.30%	34.80%
Operating Taxes		333,812
Tax Rate		13.76%
NOPAT	321,056	2,091,662
Net income	(234,015) -113.52%	1,731,370 27.89%
Dividends		(33,422)
Dividend yield		0.51%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	45,055	87,768
Long-term debt	837,286	807,091
Deferred revenue	38,212	46,657
Other long-term liabilities	60,165	64,943
Net debt	(1,116,532)	(2,683,208)
Cash flow
Cash from operating activities	(474,895)	2,153,632
CAPEX	(330,928)
Cash from investing activities	(606,421)
Cash from financing activities	(797,228)
FCF	(287,436)	2,221,316
Balance
Cash	1,947,664	3,474,899
Long term investments	51,209	103,167
Excess cash	1,878,197	3,229,573
Stockholders' equity	4,562,772	5,419,485
Invested Capital	4,051,417	3,352,496
ROIC	8.67%	60.99%
ROCE	5.40%	36.75%
EV
Common stock shares outstanding	514,318	533,269
Price	11.38 -8.00%	12.37 -16.64%
Market cap	5,852,944 -11.27%	6,596,534 -16.42%
EV	5,548,519	4,950,409
EBITDA	547,340	2,638,830
EV/EBITDA	10.14	1.88
Interest	47,062	40,060
Interest/NOPBT	14.66%	1.65%